



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 5/00, C07D 403/00, 401/00		A2	(11) International Publication Number: WO 98/27108
			(43) International Publication Date: 25 June 1998 (25.06.98)
(21) International Application Number: PCT/JP97/04243			
(22) International Filing Date: 20 November 1997 (20.11.97)			
(30) Priority Data:			
PO 4219	16 December 1996 (16.12.96)	AU	
PO 5929	1 April 1997 (01.04.97)	AU	
PO 9030	9 September 1997 (09.09.97)	AU	
(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).			
(71) Applicant (for US only): YATABE, Yoshiko (heirress of the deceased inventor) [JP/JP]; 4-1-1-421-201, Namiki, Tsukuba-shi, Ibaraki 305 (JP).			
(72) Inventor: YATABE, Takumi (deceased).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): ITOH, Yoshikuni [JP/JP]; 2-49-12, Himuro-cho, Takatsuki-shi, Osaka 569-11 (JP). INOUE, Takayuki [JP/JP]; 4-15-2-2-201, Matsushiro, Tsukuba-shi, Ibaraki 305 (JP). HAMASHIMA, Hitoshi [JP/JP]; 3-25-4-202, Matsushiro, Tsukuba-shi, Ibaraki 305 (JP). SHIMA, Ichiro [JP/JP]; 5-25-105, Gosyogaoka, Moriya-cho, Kitasouma-gun, Ibaraki 302-01 (JP). OHNE, Kazuhiko [JP/JP]; 1-16-15-A102, Ninomiya, Tsukuba-shi, Ibaraki 305 (JP). YOSHIHARA, Kousei [JP/JP]; 2-4-38-405, Manabe, Tsuchiura-shi, Ibaraki 300 (JP). OKU, Teruo [JP/JP]; 8-2, Midorigaoka, Tsukuba-shi, Ibaraki 305 (JP).			
		(74) Agent: TAKASHIMA, Hajime; Yuki Building, 3-9, Hiranomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).	
		(81) Designated States: AU, CA, CN, HU, IL, JP, KR, MX, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
		Published Without international search report and to be republished upon receipt of that report.	

(54) Title: NEW AMIDE COMPOUNDS

(57) Abstract

A compound of formula (I) wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NO-mediated

diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, synovitis, shock, diabetes, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, glomerulonephritis, peptic ulcer, inflammatory bowel disease, cerebral infarction, cerebral ischemia, cerebral hemorrhage, migraine, rheumatoid arthritis, gout, neuritis, postherpetic neuralgia, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, metastasis, Alzheimer's disease, arthritis, CNS disorders, dermatitis, hepatitis, liver cirrhosis, multiple sclerosis, pancreatitis, atherosclerosis, and the like in human being and animals.



